Company Profile
OmniAb Stock Price, News & Catalysts
- Ticker:
- OABI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.42 USD (+1.18%)
Close
Last updated: August 12, 2026
380M USD
Market cap
Why the stock is moving
As of Aug 12, 2026, OABI closed up 1.18% at $3.42. No new same-company headline was identified in the current news window.
Company overview
Business overview
OmniAb is a biotechnology platform company that monetizes antibody discovery technology through partnerships and licensing. It provides tools and engineered animal platforms to discover therapeutic antibodies.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, OmniAb sits in biotech infrastructure and discovery platforms.
Business Model Characteristics
Revenue depends on partner demand, technology adoption, and the economics of platform licensing rather than direct drug sales.
Position Within the Biotechnology Landscape
OmniAb is an enabling antibody-platform name whose value comes from discovery infrastructure and partnership monetization.
Future catalysts
- OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners. The market will care about utilization and downstream optionality more than a single headline.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of OmniAb (OABI)?
OmniAb (OABI) most recently closed at 3.42 USD, a +1.18% move versus the previous session.
What is the market cap of OmniAb (OABI)?
OmniAb currently has a market capitalization of 380M USD on BioPharmSignal.
What does OmniAb do?
OmniAb is a biotechnology platform company that monetizes antibody discovery technology through partnerships and licensing. It provides tools and engineered animal platforms to discover therapeutic antibodies.
On which exchange is OABI stock listed?
OmniAb (OABI) is associated with NASDAQ, United States, Biopharma.
What is OmniAb?
OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners.
Which conditions is OmniAb targeting with OmniAb?
OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners.
How does OmniAb describe recent progress with OmniAb?
OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners.
What future catalysts are investors watching for OmniAb?
OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners. The market will care about utilization and downstream optionality more than a single headline.